Quantitative analysis in parathyroid adenoma scintigraphy.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
19
8
2021
medline:
19
2
2022
entrez:
18
8
2021
Statut:
ppublish
Résumé
Surgery is the only curative treatment for primary hyperparathyroidism. Parathyroid scintigraphy is one method used to preoperatively localize the lesion. We examined time-related changes in radiopharmaceutical uptake in parathyroid adenomas (PTAs) and thyroid gland by quantitative single-photon-emission computed tomography (SPECT) imaging to assess differences between rapid and delayed washout patterns. The study group consisted of 35 histologically verified PTAs after radio-guided surgery extirpation in 33 patients with primary hyperparathyroidism. Patients underwent a three-phase SPECT/CT study of the neck and upper thorax post 99mTc-methoxyisobutylisonitrile (MIBI) injection. Images were reconstructed using a proprietary ordered-subset-conjugate-gradient-maximization algorithm (Siemens xSPECT Quant). PTAs were divided into those with a rapid (group A) and those with a slow (group B) washout pattern. SUVmax values of PTAs and thyroid gland tissue at 10, 90 and 180 min post 99mTc-MIBI injection were recorded and statistically assessed. Retention indexes related to the early examination were calculated for PTA and thyroid gland (RI-PTA and RI-TG). There were 11 PTAs in group A and 24 in group B. Significant between-group differences in PTA SUVmax and PTA/thyroid gland ratios were observed only at 180 min postinjection (P = 0.0297, P = 0.0222, respectively). RI-PTAs differed significantly at 90 and 180 min postinjection (P = 0.0298, P = 0.0431). No differences in PTA volumes, thyroid gland SUVmax values or RI-TG were observed between the groups. PTAs with rapid and slow washout patterns have different characteristics on quantitative analysis in later phases. No significant differences in directly measurable quantitative values (SUVmax, PTA/thyroid gland ratio) at the early stages of multi-phase examination were observed.
Identifiants
pubmed: 34406145
doi: 10.1097/MNM.0000000000001474
pii: 00006231-202201000-00001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-7Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Minisola S, Gianotti L, Bhadada S, Silverberg SJ. Classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018; 32:791–803.
Elgazzar A, Alenezi S, Asa’ad S. Scintigraphic parathyroid imaging: concepts and new developments. Res Reports Nucl Med. 2015; 5:9–18.
Bellantone R, Raffaelli M, DE Crea C, Traini E, Lombardi CP. Minimally-invasive parathyroid surgery. Acta Otorhinolaryngol Ital. 2011; 31:207–215.
Mariani G, Gulec SA, Rubello D, Boni G, Puccini M, Pelizzo MR, et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med. 2003; 44:1443–1458.
Piciucchi S, Barone D, Gavelli G, Dubini A, Oboldi D, Matteuci F. Primary hyperparathyroidism: imaging to pathology. J Clin Imaging Sci. 2012; 2:59.
Wojtczak B, Syrycka J, Kaliszewski K, Rudnicki J, Bolanowski M, Barczyński M. Surgical implications of recent modalities for parathyroid imaging. Gland Surg. 2020; 9:S86–S94.
Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med. 2007; 48:1084–1089.
Petranović Ovčariček P, Giovanella L, Carrió Gasset I, Hindié E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021; 48:2801–2822.
Moralidis E. Radionuclide parathyroid imaging: a concise, updated review. Hell J Nucl Med. 2013; 16:125–133.
Tabotta F, Jreige M, Schaefer N, Becce F, Prior JO, Nicod Lalonde M. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases. BMC Musculoskelet Disord. 2019; 20:619.
Peters SMB, van der Werf NR, Segbers M, van Velden FHP, Wierts R, Blokland KJAK, et al. Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom study. EJNMMI Phys. 2019; 6:29.
Noureldine SI, Gooi Z, Tufano RP. Minimally invasive parathyroid surgery. Gland Surg. 2015; 4:410–419.
Formánek M, Dedek V, Koláček M, Havel M, Zeleník K, Komínek P. Individualised timing of radio-guided parathyroidectomy using multi-phase SPECT/CT increases in vivo sensitivity and accuracy and reduces operating time: a randomised clinical trial. Diagnostics (Basel). 2021; 11:677.
Miyaji N, Miwa K, Tokiwa A, Ichikawa H, Terauchi T, Koizumi M, Onoguchi M. Phantom and clinical evaluation of bone SPECT/CT image reconstruction with xSPECT algorithm. EJNMMI Res. 2020; 10:71.
Kettle AG, O’Doherty MJ. Parathyroid imaging: how good is it and how should it be done? Semin Nucl Med. 2006; 36:206–211.
Nafisi Moghadam R, Amlelshahbaz AP, Namiranian N, Sobhan-Ardekani M, Emami-Meybodi M, Dehghan A, et al. Comparative diagnostic performance of ultrasonography and 99mTc-sestamibi scintigraphy for parathyroid adenoma in primary hyperparathyroidism; systematic review and meta- analysis. Asian Pac J Cancer Prev. 2017; 18:3195–3200.
Zanzonico PB, Bigler RE, Sgouros G, Strauss A. Quantitative SPECT in radiation dosimetry. Semin Nucl Med. 1989; 19:47–61.
Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging. 2017; 1:2.
Ramsay SC, Cuscaden C. The current status of quantitative SPECT/CT in the assessment of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2020; 27:1464–1468.
Dong F, Li L, Bian Y, Li G, Han X, Li M, et al. Standardized uptake value using thyroid quantitative SPECT/CT for the diagnosis and evaluation of graves’ disease: a prospective multicenter study. Biomed Res Int. 2019; 2019:7589853.
Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019; 46:751–765.
Parvinian A, Martin-Macintosh EL, Goenka AH, Durski JM, Mullan BP, Kemp BJ, et al. 11 C-choline PET/CT for detection and localization of parathyroid adenomas. Am J Roentgenol. 2018; 210:418–422.
Prabhu M, Damle NA. Fluorocholine PET imaging of parathyroid disease. Indian J Endocrinol Metab. 2018; 22:535–541.
Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, et al. Benefit of 18 F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol. 2018; 28:2700–2707.
Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg. 2016; 401:925–935.
Robin P, Klein R, Gardner J, Ziebarth B, Bazarjani S, Razavi S, et al. Quantitative analysis of technetium-99m-sestamibi uptake and washout in parathyroid scintigraphy supports dual mechanisms of lesion conspicuity. Nucl Med Commun. 2019; 40:469–476.
Cheon M, Choi JY, Chung J-H, Lee JY, Cho SK, Yoo J, et al. Differential findings of tc-99m sestamibi dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism. Nucl Med Mol Imaging (2010). 2011; 45:276–284.
Pons F, Torregrosa JV, Fuster D. Biological factors influencing parathyroid localization. Nucl Med Commun. 2003; 24:121–124.
Dickson J, Ross J, Vöö S. Quantitative SPECT: the time is now. EJNMMI Phys. 2019; 6:4.
Razavi S, Ziebarth B, Klein R, Zeng W. Dual time-point quantitative SPECT-CT parathyroid imaging using a single computed tomography: feasibility and operator variability. Nucl Med Commun. 2018; 39:3–9.
Zhang M, Sun L, Rui W, Guo R, He H, Miao Y, et al. Semi-quantitative analysis of 99mTc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma. Quant Imaging Med Surg. 2019; 9:1394–1401.